The weekly litigation news digest is live. Subscribe now

IP Verse

Cladribine Regimen For Treating Multiple Sclerosis - EP2805723

The patent EP2805723 was granted to Merck Serono on Jan 17, 2018. The application was originally filed on Dec 20, 2005 under application number EP14001970A. The patent is currently recorded with a legal status of "Revoked".

EP2805723

MERCK SERONO
Application Number
EP14001970A
Filing Date
Dec 20, 2005
Status
Revoked
Oct 17, 2023
Publication Date
Jan 17, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Oral Cladribine treatment regimen for multiple sclerosis that allows reduced dosing and fewer side effects compared to IV or SC administration. The regimen involves multiple cycles of 1-7 days of oral Cladribine followed by Cladribine-free periods. The total Cladribine dose is lower during maintenance periods. This sequential oral dosing reduces side effects while still providing MS lesion suppression.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKOct 16, 2018ELKINGTON AND FIFE -

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0173059
DESCRIPTIONEP0626853
DESCRIPTIONUS5208327
DESCRIPTIONUS5506214
DESCRIPTIONUS6194395
DESCRIPTIONWO0064918
DESCRIPTIONWO2004028462
DESCRIPTIONWO2004087100
DESCRIPTIONWO2004087101
DESCRIPTIONWO9619229
DESCRIPTIONWO9619230
OPPOSITIONWO2004087101
SEARCHEP0626853
SEARCHWO2004087101

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents